(Q38661075)

5 September 2017

title

Current issues in the economics of vaccination against dengue (English)

1 reference

5 September 2017

0 references

Yesim Tozan

1

1 reference

5 September 2017

publication date

5 December 2015

1 reference

Expert Review of Vaccines

5 September 2017

published in

1 reference

5 September 2017

volume

15

1 reference

5 September 2017

issue

4

1 reference

5 September 2017

page(s)

519-528

1 reference

The Epidemiology of Dengue in the Americas Over the Last Three Decades: A Worrisome Reality

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

The global emergence/resurgence of arboviral diseases as public health problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Dengue in Southeast Asia: epidemiological characteristics and strategic challenges in disease prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Dengue: a continuing global threat

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

The history of dengue outbreaks in the Americas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Refining the global spatial limits of dengue virus transmission by evidence-based consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Reviewing dengue: still a neglected tropical disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Evaluation of diagnostic tests: dengue

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Cost of dengue outbreaks: literature review and country case studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Health economics of dengue: a systematic literature review and expert panel's assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Economic and disease burden of dengue in Southeast Asia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

The health and economic impact of dengue in Latin America

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Dengue vector-control services: how do they work? A systematic literature review and country case studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Effect of dengue vector control interventions on entomological parameters in developing countries: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Efficacy of a tetravalent dengue vaccine in children in Latin America.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Policymakers’ views on dengue fever/dengue haemorrhagic fever and the need for dengue vaccines in four southeast Asian countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Dengue vaccine roll-out: getting ahead of the game

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

A Multi-country Study of the Household Willingness-to-Pay for Dengue Vaccines: Household Surveys in Vietnam, Thailand, and Colombia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Will dengue vaccines be used in the public sector and if so, how? Findings from an 8-country survey of policymakers and opinion leaders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

The demand for a dengue vaccine: a contingent valuation survey in Metro Manila

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

The global value of vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

The contribution of vaccination to global health: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Updating the evidence base on the operational costs of supplementary immunization activities for current and future accelerated disease control, elimination and eradication efforts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Cost-effectiveness and economic benefits of vaccines in low- and middle-income countries: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Projections of costs, financing, and additional resource requirements for low- and lower middle-income country immunization programs over the decade, 2011-2020.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

The imperative for stronger vaccine supply and logistics systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Overcoming challenges to sustainable immunization financing: early experiences from GAVI graduating countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Cost-effectiveness analyses of vaccination programmes : a focused review of modelling approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Methodological issues and new developments in the economic evaluation of vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Models of the impact of dengue vaccines: a review of current research and potential approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Dynamic epidemiological models for dengue transmission: a systematic review of structural approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Dengue vaccines: dawning at last?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Potential opportunities and perils of imperfect dengue vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Controlling dengue with vaccines in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Transmission dynamics of the four dengue serotypes in southern Vietnam and the potential impact of vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Neutralization and antibody-dependent enhancement of dengue viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Cost-effectiveness of a pediatric dengue vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Economic value of dengue vaccine in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Economic impact of dengue illness and the cost-effectiveness of future vaccination programs in Singapore

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Dengue dynamics and vaccine cost-effectiveness in Brazil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Using economic evaluation in policy decision-making in Asian countries: mission impossible or mission probable?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Results from evaluations of models and cost-effectiveness tools to support introduction decisions for new vaccines need critical appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Economic analyses to support decisions about HPV vaccination in low- and middle-income countries: a consensus report and guide for analysts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

The introduction of new vaccines into developing countries. V: Will we lose a decade or more in the introduction of dengue vaccines to developing countries?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Cost of production of live attenuated dengue vaccines: a case study of the Instituto Butantan, Sao Paulo, Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Preparing for dengue vaccine introduction in ASEAN countries: recommendations from the first ADVA regional workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Health seeking and access to care for children with suspected dengue in Cambodia: an ethnographic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Public acceptance and willingness-to-pay for a future dengue vaccine: a community-based survey in Bandung, Indonesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Role of the private sector in the provision of immunization services in low- and middle-income countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Delivery cost of human papillomavirus vaccination of young adolescent girls in Peru, Uganda and Viet Nam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Vaccine supply chains need to be better funded and strengthened, or lives will be at risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

How much does it cost to get a dose of vaccine to the service delivery location? Empirical evidence from Vietnam's Expanded Program on Immunization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Introducing new vaccines in the poorest countries: what did we learn from the GAVI experience with financial sustainability?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Challenges to building capacity for evidence-based new vaccine policy in developing countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Preparing for dengue vaccine introduction: recommendations from the 1st dengue v2V International Meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Sustaining GAVI-supported vaccine introductions in resource-poor countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Monitoring of progress in the establishment and strengthening of national immunization technical advisory groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Strategies for financial sustainability of immunization programs: a review of the strategies from 50 national immunization program financial sustainability plans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Preparing for introduction of a dengue vaccine: recommendations from the 1st Dengue v2V Asia-Pacific Meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Trials and tribulations on the path to developing a dengue vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

New immunization initiatives and progress toward the global control of hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Systematic review of studies evaluating the broader economic impact of vaccination in low and middle income countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

During the 'decade of vaccines,' the lives of 6.4 million children valued at $231 billion could be saved.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

Valuing the broader benefits of dengue vaccination, with a preliminary application to Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1129278

10.1586/14760584.2016.1129278

21 January 2018

Identifiers

DOI

1 reference

5 September 2017

1 reference